Personalized tumor-specific DNA junctions to detect circulating tumor in patients with endometrial cancer.

ABSTRACT:

Introduction

There are no reliable blood biomarkers for monitoring endometrial cancer patients in the current clinical practice. Circulating tumor DNA (ctDNA) is emerging as a promising non-invasive method to measure tumor burden, define prognosis and monitor disease status in many solid cancers. In this pilot study, we investigated if unique tumor-specific DNA junctions can be used to detect ctDNA levels in patients with endometrial cancer.

Methods

Chromosomal rearrangements in primary tumors of eleven patients with high-grade or advanced stage endometrial cancer were determined by whole-genome Mate-Pair sequencing. Identified unique tumor-specific junctions were evaluated in pre- and six-week post-surgery patient plasma using individualized quantitative polymerase chain re

SUBMITTER: Grassi T 

PROVIDER: S-EPMC8192008 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature